News
Protagonist Therapeutics, Inc.Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback